乌贡因通过通过促进miR-4799-5p表达抑制甲素V通过促进miR-4799-5p表达抑制冠状腺癌转移的转移
Nguyen Bao Tran1, Ting-Kuo Chang2,3, Nguyen Duong Phuong Chi4
1Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan, 404.
International journal of biological sciences
|February 3, 2025
概括
乌贡因V是一种植物衍生的黄类化合物,通过向甲素V (CTS V) 表达,有效地抑制冠状动脉瘤转移. 这种新的治疗方法抑制了癌细胞的迁移和入侵,为治疗这种罕见的骨癌提供了新的希望.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 软骨肉瘤是一种罕见的骨癌,发病率不断增加,治疗结果不佳,特别是在晚期.
- 转移和对传统疗法的耐药性需要开发新的治疗策略.
- 乌贡因V是一种来自*Helminthostachys zeylanica*的黄类化合物,因其抗癌潜力而受到研究.
研究的目的:
- 调查乌贡因V在抑制冠状腺癌转移中的分子机制.
- 为了识别Ugonin V在软骨肉瘤进展中的关键分子标.
- 评估Ugonin V对冠状腺癌转移的治疗潜力.
主要方法:
- 对软骨肉瘤基因表达数据集 (GSE30835) 的分析,以确定上调调节的蛋白酶.
- 在体外和体内研究,以评估Ugonin V对冠状腺癌细胞运动性和转移的作用.
- miRNA测序以识别涉及Ugonin V作用机制的微RNA.
主要成果:
- 甲素 (CTS) A,L和V在软骨肉瘤组织中显著上调.
- 乌贡因V特异性抑制了甲素V (CTS V) 的mRNA表达.
- 乌贡因V通过通过miR-4799-5p调节CTSV表达来抑制胆固醇瘤细胞运动和侵入.
结论:
- 乌贡因V在冠状腺癌中表现出强大的抗转移作用.
- 这项研究发现了一种新的治疗途径,涉及乌贡因V,CTSV和miR-4799-5p.
- 乌戈宁V是开发新型冠状腺癌治疗的有希望的候选者.
相关概念视频
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
MicroRNAs
3.0K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K


